التفاصيل البيبلوغرافية
| العنوان: |
USE OF CURCUMIN OR ITS ANALOGUES IN CANCER THERAPY UTILIZING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR |
| Document Number: |
20110224205 |
| تاريخ النشر: |
September 15, 2011 |
| Appl. No: |
13/025798 |
| Application Filed: |
February 11, 2011 |
| مستخلص: |
Provided is combined use of an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and curcumin or its analogue in cancer therapy, which reduces side effects resulting from the EGFR-TKI and reduces doses of the EGFR-TKI needed for the therapy, particular in a patient resistant to the treatment with the EGFR-TKI alone. |
| Inventors: |
Chen, Huei-Wen (Taipei City, TW); Lee, Jen-Yi (Taichung City, TW); Yang, Pan-Chyr (Taipei City, TW); Yu, Sung-Liang (Taipei City, TW); Chen, Jian-Wei (Taichung City, TW); Yang, Chih-Hsin (Taipei City, TW); Ho, Chao-Chi (Taipei City, TW); Lee, Kuo-Hsiung (Chapel Hill, NC, US); Tseng, Yufeng Jane (Taipei City, TW); Chang, Gee-Chen (Taichung City, TW) |
| Assignees: |
NATIONAL TAIWAN UNIVERSITY (TAIPEI CITY, TW) |
| Claim: |
1. A method for reducing side effects resulting from treatment using an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), comprising administering curcumin or its analogue to a patient undergoing such treatment in an amount effective to reduce the side effects. |
| Claim: |
2. The method of claim 1, wherein the side effects are EGFR-TKI induced adverse gastrointestinal effects. |
| Claim: |
3. The method of claim 2, wherein the side effects are EGFR-TKI induced intestinal cell damage or growth inhibition. |
| Claim: |
4. The pharmaceutical composition of claim 1, wherein the EGFR-TKI is gefitinib (N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine). |
| Claim: |
5. The method of claim 1, wherein the analogue is selected from the group consisting of [chemical expression included] |
| Claim: |
6. The method of claim 1, wherein the patient is afflicted with non-small-cell lung cancer (NSCLC). |
| Claim: |
7. The method of claim 1, wherein the curcumin or its analogue is administered concurrently with the EGFR-TKI. |
| Claim: |
8. A method for administering an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to a patient in need of a cancer therapy using the EGFR-TKI, comprising administering to the patient a reduced dose of the EGFR-TKI in combination with curcumin or its analogue while efficacy of the EGFR-TKI with respect to the cancer therapy is substantially maintained as compared to that achieved with a standard dose of the EGFR-TKI without administration of the curcumin or its analogue. |
| Claim: |
9. The method of claim 8, wherein the reduced dose is about 50% or less of the standard therapeutic dose of the EGFR-TKI. |
| Claim: |
10. The method of claim 8, wherein the patient is afflicted with NSCLC. |
| Claim: |
11. The method of claim 8, wherein the patient is resistant to treatment with the EGFR-TKI alone. |
| Claim: |
12. The pharmaceutical composition of claim 8, wherein the EGFR-TKI is gefitinib (N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine). |
| Claim: |
13. The method of claim 8, wherein the analogue is selected from the group consisting of: [chemical expression included] |
| Claim: |
14. The method of claim 8, wherein the curcumin or its analogue is administered concurrently with the EGFR-TKI. |
| Claim: |
15. A method for treating a cancer patient with resistance to an EGFR-TKI, which comprises jointly administering to said patient an effective amount of the EGFR-TKI with curcumin or its analogue. |
| Current U.S. Class: |
5142/345 |
| Current International Class: |
61; 61; 61 |
| رقم الانضمام: |
edspap.20110224205 |
| قاعدة البيانات: |
USPTO Patent Applications |
